China (Mainland)
Osimertinib (AZD9291) CAS NO.1421373-65-0
- Min.Order: 0 Metric Ton
- Payment Terms:
- Product Details
Keywords
- Osimertinib
- AZD9291
- 1421373-65-0
Quick Details
- ProName: Osimertinib (AZD9291)
- CasNo: 1421373-65-0
- Molecular Formula: C28H33N7O2
- ProductionCapacity: Metric Ton/Day
- Purity: >97%
- LimitNum: 0 Metric Ton
Superiority
Biological Activity
| Description | Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3. | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Features | Orally bioavailable mutant-selective EGFR inhibitor that has been tested in Phase III clinical trials for treatment of Non-Small Cell Lung Cancer. | ||||||||||||||||||||||||||||||
| Targets |
|
||||||||||||||||||||||||||||||
| In vitro |
AZD9291 shows significantly more potent inhibition of proliferation in mutant EGFR cell lines compared to wild-type in vitro. [2] |
||||||||||||||||||||||||||||||
| Cell Data |
|
||||||||||||||||||||||||||||||
| Assay |
|
||||||||||||||||||||||||||||||
| In vivo | AZD9291(5mg/kg p.o.) causes profound regression of tumors across EGFRm+ (PC9) and EGFRm+/T790M (H1975) tumor models with profound inhibition of EGFR phosphorylation and key downstream signaling pathways such as AKT and ERK in vivo. [2] |